Carparts.Com Inc vs GeneDx Holdings Corp — how do they compare? Carparts.Com Inc trades at $8.6 (market cap $66.42M), while GeneDx Holdings Corp trades at $69.32 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 30.4× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and GeneDx Holdings Corp for 19 Days on average.
| PRTS | WGS | |
|---|---|---|
Market Cap | $66.42M | $2.02B |
Volume | 40,287 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $167.51 |
52-Week Low | $3.88 | $34.51 |
Typical Hold Time | 45 Days | 19 Days |
Enterprise Value | $79.39M | $2.05B |
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.
The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →